Refacto Market Report 2026

Refacto Market Overview

• The Refacto market growth in the historic period has been driven by increased diagnosis of hemophilia a, transition from plasma-derivedrecombinant therapies • Market expansion is supported by expansion of long-acting clotting factor products, rising demand for personalized hemophilia care • Growth Driver: Rising Healthcare Expenditure Driving Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Refacto Market?

Refacto is a recombinant factor VIII product used to treat hemophilia A, a genetic disorder where patients lack sufficient clotting factor, leading to prolonged bleeding. It helps replace the missing factor VIII to prevent or control bleeding episodes in affected individuals. The main clinical indications of refacto include prophylaxis, on-demand treatment, perioperative management, and immune tolerance induction (ITI). Prophylaxis is a treatment approach aimed at preventing a medical condition from occurring. In the context of hemophilia, prophylactic treatment involves regular infusion of clotting factor concentrates to prevent bleeding episodes before they happen. The various formulations include powder for injection and pre-filled syringes and are distributed through channels including hospital pharmacies, retail pharmacies, and specialty pharmacies and are used by multiple end users, such as pediatric, adult, and geriatric.

What Is The Refacto Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of long-acting clotting factor products, rising demand for personalized hemophilia care, increasing investments in recombinant biologics, growing focus on home-based treatment models, advancements in gene and protein therapy integration. Major trends in the forecast period include increasing adoption of recombinant clotting factors, expansion of prophylactic hemophilia treatment, growing use of pre-filled syringe formats, enhanced focus on bleeding prevention protocols, improved manufacturing yield of recombinant proteins.

Global Refacto Market Segmentation

1) By Clinical Indication: Prophylaxis, On-Demand Treatment, Perioperative Management, Immune Tolerance Induction (ITI) 2) By Formulation: Powder For Injection, Pre-Filled Syringes 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies 4) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Refacto Market?

Increasing healthcare expenditure is expected to propel the growth of the refacto market going forward. Healthcare expenditure refers to the total spending on medical services, products, and public health initiatives aimed at maintaining and improving health. Healthcare expenditure is rising due to an aging population requiring more medical care and the growing prevalence of chronic diseases like diabetes and heart conditions. Healthcare expenditure on Refacto drugs is allocated to support their development, production, and accessibility for treating hemophilia and related conditions. Healthcare expenditure is beneficial for refacto, as increased investment in hemophilia treatments drives demand for advanced therapies like refacto, enabling better access to treatment, promoting long-term cost savings through reduced hospitalizations and complications, and enhancing patient adherence to therapy, ultimately supporting market growth. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK rose by 5.6%, a significant increase compared to the 0.9% growth in 2022, with the total healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the refacto industry. The rising prevalence of hemophilia A is expected to propel the growth of the Refacto market going forward. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, leading to impaired blood clotting and prolonged bleeding even from minor injuries. Hemophilia A is increasing mainly because improved diagnostic capabilities are identifying more cases with greater accuracy. Refacto supports hemophilia A by replacing the missing factor VIII to improve blood clotting and reduce bleeding episodes for better long-term disease management. For instance, in May 2024, according to the US Centers for Disease Control and Prevention (CDC), a US-based government agency, an estimated 33,000 males in the United States are living with hemophilia. Therefore, the rising prevalence of hemophilia A is driving the growth of the Refacto industry. The increasing number of drug approvals is anticipated to drive the growth of the refacto market in the future. Drug approvals are the regulatory process where agencies evaluate and authorize a drug for public use, ensuring it is safe, effective, and high-quality. Drug approvals are rising due to advancements in technology, streamlined regulatory processes, increased investment in biotechnology, and a focus on rare diseases and personalized medicine. Refacto helps streamline drug approval by serving as a proven, recombinant therapy for hemophilia A, demonstrating consistent safety and efficacy in clinical trials, which supports regulatory confidence and accelerates the approval of similar innovative treatments in the hemophilia market. For instance, in January 2024, according to the National Institutes of Health, a US-based government agency, in 2023, the U.S. Food and Drug Administration (FDA) approved 55 new drugs, compared to 37 drugs authorized in 2022. Therefore, the rising number of drug approvals is driving the growth of the refacto industry.

Key Players In The Global Refacto Market

Major companies operating in the refacto market are Pfizer Inc.

Regional Insights

North America was the largest region in the refacto market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Refacto Market?

The refacto market consists of sales of products including recombinant factor VIII products, extended half-life recombinant factor VIII products, and plasma-derived factor VIII products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Refacto Market Report 2026?

The refacto market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the refacto industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.